THREE YEARS OF ENTECAVIR (ETV) RE-TREATMENT OF HBEAG(-) ETV PATIENTS WHO PREVIOUSLY DISCONTINUED ETV TREATMENT: RESULTS FROM STUDY ETV-901

被引：0
|
作者：
Shouval, Daniel [1 ]
Lai, Ching-Lung [2 ]
Chang, Ting-Tsung [3 ]
Gadano, Adrian [4 ]
Wu, Shun-Sheng [5 ]
Halota, Waldemar [6 ]
Sievert, William [7 ]
Tsai, Naoky C. S. C. [8 ]
Zhang, Hui [9 ]
Iloeje, Uchenna [9 ]
机构：
[1] Hadassah Med Org, Liver Unit, Jerusalem, Israel
[2] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[3] Natl Cheng Kung Univ, Coll Med, Dept Internal Med, Tainan 70101, Taiwan
[4] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[5] Changhua Christian Hosp, Dept Internal Med, Changhua, Taiwan
[6] Klin Chorob Zakaznych AM, Bydgoszcz, Poland
[7] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia
[8] Univ Hawaii, Honolulu, HI 96822 USA
[9] Bristol Myers Squibb Co, Res & Dev, Wallingford, CT 06492 USA
来源：
HEPATOLOGY | 2008年 / 48卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
927
引用
收藏
页码：722A / 723A
页数：2
相关论文
共 50 条
  • [21] Entecavir (ETV) demonstrates consistent responses throughout baseline demographic subgroups for the treatment of nucleosidenaive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B
    Shouval, D
    Senturk, H
    Gish, RG
    Chang, TT
    Yurdaydin, C
    Lai, CL
    Lok, AS
    Brown, RS
    Apelian, D
    Fernandes, L
    Klesezewski, K
    Cross, A
    Wilber, R
    JOURNAL OF HEPATOLOGY, 2005, 42 : 192 - 192
  • [22] Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of Phase III study ETV-022 in nucleoside-naive patients
    Chang, TT
    Gish, R
    de Man, R
    Gadano, A
    Sollano, J
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    DeHertogh, D
    Apelian, D
    ANTIVIRAL THERAPY, 2004, 9 (06) : H21 - H22
  • [23] Continued virologic improvement through 96 weeks of Entecavir treatment in HBeAg(-) chronic hepatitis B patients (STUDY ETV-027)
    Poordad, Fred
    Dieterich, Douglas T.
    Min, Albert D.
    Shouval, Daniel
    Lai, Ching-Lung
    Cheinquer, Hugo
    Chang, Ting-Tsung
    Zink, Richard
    Zhu, Jin
    Brett-Smith, Helena
    GASTROENTEROLOGY, 2006, 130 (04) : A848 - A848
  • [24] Long-term follow-up of entecavir treated protocol-defined non-responders in rollover study ETV-901
    Sherman, Morris
    Rizzetto, Mario
    Lai, Ching Lung
    Liaw, Yun-Fan
    Gadano, Adrian
    Jacobson, Ira M.
    Schiff, Eugene R.
    Yang, Joanna
    Colonno, Richard
    Kreter, Bruce
    Hindes, Robert
    HEPATOLOGY, 2007, 46 (04) : 682A - 683A
  • [25] Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: Results of phase III study ETV-022 in nucleoside-naive patients
    Chang, TT
    Gish, R
    de Man, R
    Gadano, A
    Sollano, J
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    Dehertogh, D
    Apelian, D
    HEPATOLOGY, 2004, 40 (04) : 193A - 193A
  • [26] Long-term follow-up of entecavir treated protocol-defined non-responders in rollover study ETV-901
    Chang, T. T.
    Wu, S. S.
    Desmond, P.
    Sollano, J.
    Lee, S. D.
    Rafalsky, V.
    Sherman, M.
    Rizzetto, M.
    Terg, R.
    Goncales, F. L., Jr.
    Gadano, A.
    Jacobson, I.
    Schiff, E.
    Yang, J.
    Tenney, D.
    Kreter, B.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A30 - A30
  • [27] LONG-TERM ENTECAVIR TREATMENT FOR UP TO 5 YEARS IN ASIANS WITH HBEAG-POSITIVE NUCLEOS(T)IDE NAiVE CHRONIC HEPATITIS B: RESULTS FROM ETV-022 AND-901
    Pan, Calvin
    Tong, Myron J.
    Kowdley, Kris V.
    Hu, Ke-Qin
    Chang, Ting-Tsung
    Lai, Ching-Lung
    Yoon, Seung Kew
    Lee, Samuel S.
    Cohen, David S.
    Tang, Hong
    Tsai, Naoky C. S. C.
    HEPATOLOGY, 2010, 52 (04) : 557A - 557A
  • [28] Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Lai, Ching-Lung
    Chang, Ting-Tsung
    Chao, You-Chen
    Tanwandee, Tawesak
    Thongsawat, Satawat
    Lee, Shou-Dong
    Angus, Peter
    Zink, Richard
    Zhu, Jin
    Brett-Smith, Helena
    Neo, Boon-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A31 - A31
  • [29] Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: Results of phase III study ETV-026
    Sherman, M
    Yurdaydin, C
    Sollano, J
    Silva, M
    Goodman, Z
    Chen, L
    Cross, A
    Dehertogh, D
    Hindes, R
    HEPATOLOGY, 2004, 40 (04) : 664A - 664A
  • [30] Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Shouval, D.
    Akarca, U. S.
    Hatzis, G.
    Kitis, G.
    Lai, C. L.
    Cheinquer, H.
    Chang, T. T.
    Zink, R.
    Zhu, J.
    Brett-Smith, H.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S21 - S22
12345